Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Channing J Der

Showing results (21-30 of 236) with videos related to

Pageof 24
Sort By:
Cold Spring Harbor Perspectives in Medicine|December 13, 2017
KRAS: The Critical Driver and Therapeutic Target for Pancreatic CancerAndrew M Waters, Channing J Der
Cancer Discovery|January 16, 2013
Mutant and wild-type Ras: co-conspirators in cancerTikvah K Hayes, Channing J Der
Oncogene|December 10, 2003
The dark side of Ras: regulation of apoptosisAdrienne D Cox, Channing J Der
Small Gtpases|September 23, 2016
Filling GAPs in our knowledge: ARHGAP11A and RACGAP1 act as oncogenes in basal-like breast cancersCampbell D Lawson, Channing J Der
The Lancet. Oncology|July 26, 2011
Are all KRAS mutations created equal?Thomas E Stinchcombe, Channing J Der
Cancer Discovery|June 5, 2019
RAS Mutations Are Not Created EqualG Aaron Hobbs, Channing J Der
Genes & Development|December 5, 2024
"Undruggable KRAS": druggable after allAdrienne D Cox, Channing J Der
Molecular Cell|July 21, 2023
KRAS regulation of miRNA: Stepping on the brake to go fasterClint A Stalnecker, Channing J Der
Proceedings of the National Academy of Sciences of the United States of America|August 1, 2015
Seeing is believing: Ras dimers observed in live cellsMark R Philips, Channing J Der
Science Signaling|March 27, 2020
RAS, wanted dead or alive: Advances in targeting RAS mutant cancersClint A Stalnecker, Channing J Der
Pageof 24

Showing results (21-30 of 236) with videos related to

Sort By:
Pageof 24
Cold Spring Harbor Perspectives in Medicine|December 13, 2017
KRAS: The Critical Driver and Therapeutic Target for Pancreatic CancerAndrew M Waters, Channing J Der
Cancer Discovery|January 16, 2013
Mutant and wild-type Ras: co-conspirators in cancerTikvah K Hayes, Channing J Der
Oncogene|December 10, 2003
The dark side of Ras: regulation of apoptosisAdrienne D Cox, Channing J Der
Small Gtpases|September 23, 2016
Filling GAPs in our knowledge: ARHGAP11A and RACGAP1 act as oncogenes in basal-like breast cancersCampbell D Lawson, Channing J Der
The Lancet. Oncology|July 26, 2011
Are all KRAS mutations created equal?Thomas E Stinchcombe, Channing J Der
Cancer Discovery|June 5, 2019
RAS Mutations Are Not Created EqualG Aaron Hobbs, Channing J Der
Genes & Development|December 5, 2024
"Undruggable KRAS": druggable after allAdrienne D Cox, Channing J Der
Molecular Cell|July 21, 2023
KRAS regulation of miRNA: Stepping on the brake to go fasterClint A Stalnecker, Channing J Der
Proceedings of the National Academy of Sciences of the United States of America|August 1, 2015
Seeing is believing: Ras dimers observed in live cellsMark R Philips, Channing J Der
Science Signaling|March 27, 2020
RAS, wanted dead or alive: Advances in targeting RAS mutant cancersClint A Stalnecker, Channing J Der
Pageof 24